Compare Indonesia Energy Corporation Limited (INDO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Recursion Pharmaceuticals Inc — how do they compare? Indonesia Energy Corporation Limited trades at $3.01 (market cap $46.01M), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 33.3× Indonesia Energy Corporation Limited's market cap. Which is the better fit depends on your goals.
| INDO | RXRX | |
|---|---|---|
Market Cap | $46.01M | $1.53B |
Sector | Energy | Health |
52-Week High | $6.74 | $6.79 |
52-Week Low | $2.49 | $2.84 |
Enterprise Value | $41.38M | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.99, down 1.32% today, with a bullish technical signal from moving averages and oscillators. The company shows negative profitability metrics including -253.4% net income margin but maintains 100% analyst buy ratings. Recent operational milestones include commencement of drilling at the Kruh Block, providing potential catalysts for future revenue growth.
While current financials show significant losses, analyst optimism and recent operational progress suggest turnaround potential. Key risks include execution challenges in oil exploration and sustained negative cash flow. The stock presents speculative opportunity for investors betting on successful well development and future profitability improvement.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
